Screening, identification of prostate cancer urinary biomarkers and verification of important spots
- 62 Downloads
Prostate-specific antigen (PSA) has been widely used as the unique serum biomarker for the diagnosis of prostate cancer (PCa). When PSA is moderately increased (e.g., 4–10 ng/ml), it is difficult to differentiate benign prostatic hyperplasia (BPH) from cancer. The diagnostic test (i.e., prostate biopsy) is invasive, adding pain and economic burden to the patient. Urine samples are more convenient, non-invasive and readily available than blood. We sought to determine whether ferritin might be the potential urinary biomarker in prostate cancer diagnosis. Using two-dimensional electrophoresis (2DE) followed by mass spectrometry (MS), differentially expressed urinary proteins among patients with PCa, BPH and normal controls were obtained. The ferritin heavy chain (FTH) gene, ferritin light chain (FTL) gene and protein expression of BPH-1 cells and PC-3 cells were analyzed by real-time quantitative PCR and Western blotting, respectively. Stable FTH or FTL silenced cell lines were generated by small hairpin(sh) RNA lentiviral transfection. The function of the cell lines was evaluated by the colony formation assay, transwell assay, and flow cytometry. Compared with BPH and normal controls, 15 overexpressed proteins, including FTH and FTL, were identified in the urine of the PCa group. FTH and FTL were also highly expressed in PC-3 cell lines compared with BPH-1 cells. FTH-silenced cells showed reduced cell proliferation, migration and increased cell apoptosis. FTL-silenced cells showed increased proliferation and migration abilities. There are differences in urinary proteins among patients with PCa, BPH and normal controls. FTH and FTL play different roles in PCa cells and are potential biomarkers for PCa.
KeywordsUrinary proteomics Prostate cancer (PCa) Benign prostatic hyperplasia (BPH) Ferritin RNA interference
Compliance with ethical standards
Conflicts of interest
Huijun Zhao, Xuhong Zhao, Ting Lei, Man Zhang declare that they have no conflicts of interest.
This work was supported by the Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20150701) and the Beijing Natural Science Foundation (7172106).
All procedures performed in studies involving human participants were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
- 2.Thompson IM (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level <= 4.0 ng per milliliter (vol 350, pg 2239, 2004). N Engl J Med 351(14):1470–1470Google Scholar
- 3.Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK, Team PP (2005) Prostate Cancer screening in the prostate, lung, colorectal and ovarian (PLCO) Cancer screening trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 97(6):433–438. https://doi.org/10.1093/jnci/dji065 CrossRefPubMedGoogle Scholar
- 4.Pieper R, Gatlin CL, McGrath AM, Makusky AJ, Mondal M, Seonarain M, Field E, Schatz CR, Estock MA, Ahmed N, Anderson NG, Steiner S (2004) Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 4(4):1159–1174CrossRefGoogle Scholar
- 5.Adachi J, Kumar C, Zhang YL, Olsen JV, Mann M (2006) The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol 7(9)Google Scholar
- 12.Meng Q, Lei T, Zhang M, Zhao J, Zhao XH, Zhang M (2013) Identification of proteins differentially expressed in adriamycin-resistant (pumc-91/ADM) and parental (pumc-91) human bladder cancer cell lines by proteome analysis. J Cancer Res Clin Oncol 139(3):509–519. https://doi.org/10.1007/s00432-012-1350-8 CrossRefPubMedGoogle Scholar
- 30.Min PJRC (2015) Role of ferritin in Cancer biology. J Cancer Sci Ther 07(5)Google Scholar
- 31.Li RS, Luo C, Mines M, Zhang JW, Fan GH (2006) Chemokine CXCL12 induces binding of ferritin heavy chain to the chemokine receptor CXCR4, alters CXCR4 signaling, and induces phosphorylation and nuclear translocation of ferritin heavy chain. J Biol Chem 281(49):37616–37627. https://doi.org/10.1074/jbc.M607266200 CrossRefPubMedGoogle Scholar
- 34.Aung W, Hasegawa S, Furukawa T, Saga T (2007) Potential role of ferritin heavy chain in oxidative stress and apoptosis in human mesothelial and mesothelioma cells: implications for asbestos-induced oncogenesis. Carcinogenesis 28(9):2047–2052. https://doi.org/10.1093/carcin/bgm090 CrossRefPubMedGoogle Scholar
- 36.Tesfay L, Huhn AJ, Hatcher H, Torti FM, Torti SV (2012) Ferritin blocks inhibitory effects of two-chain high molecular weight kininogen (HKa) on adhesion and survival signaling in endothelial cells. PLoS One 7(7):e40030. https://doi.org/10.1371/journal.pone.0040030 CrossRefPubMedPubMedCentralGoogle Scholar